Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab in Treatment-Experienced HIV-1
NCT03902522Phase 3Completed
- Sponsor
- CytoDyn Inc.
- Start
- Jun 2018
- Primary completion
- May 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leronlimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by CytoDyn Inc. Primary endpoint: Proportion of Participants With >= 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at 1 week. Started Jun 2018; status: completed.
02
Drugs
leronlimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03902522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902522.